Acolbifene/prasterone (tentative brand name Femivia) is a combination formulation of acolbifene, a selective estrogen receptor modulator, and prasterone (dehydroepiandrosterone; DHEA), an androgen, estrogen, and neurosteroid, which is under development by Endoceutics for the treatment of vasomotor symptoms (hot flashes) in postmenopausal women.[1] It is intended for use by mouth.[1] As of December 2017, it is in phase III clinical trials for this indication.[1]
| Combination of | |
|---|---|
| Acolbifene | Selective estrogen receptor modulator |
| Prasterone | Androgen |
| Clinical data | |
| Trade names | Femivia (tentative) |
| Other names | Prasterone/acolbifene; Acolbifene/DHEA; DHEA/Acolbifene |
| Routes of administration | By mouth |
See also
editReferences
editExternal links
edit- Acolbifene/prasterone - AdisInsight
- Pipeline - Endoceutics Archived 2017-10-18 at the Wayback Machine
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |